Epidemiological studies
The lymphoma group has a keen interest in epidemiological studies on lymphoma and related diseases. We collaborate both within the Nordic Lymphoma group and with other international institutions.
Ongoing projects include:
Long-term outcomes in patients with SMZL treated in the Rituximab Era. With the NLG epidemilology group Home - Nordic-lymphoma : Nordic-lymphoma . Headed by Aalborg University Hospital (Tarec El-Galaly og Ahmed Ludvigsen Al-Mashhadi) - Department of Haematology — Aalborg University's Research Portal (aau.dk) Tarec Christoffer El-Galaly — Aalborg Universitets forskningsportal (aau.dk)
Life after Lymphoma - how can we individualize treatment and care to reduce complications and improve lymphoma survivorship in the Nordic countries. . With the NLG epidemilology group Home - Nordic-lymphoma : Nordic-lymphoma . Headed by Karin E Smedby, Karolinska Institutet, Sweden Clinical Cancer Epidemiology – Research group Karin Ekström Smedby | Karolinska Institutet (ki.se)
Mantle cell lymphoma survival in Norway and Denmark - how does difference in availability of Ibrutinib impact survival at population level? Collaboration with NLG epidemilology group Home - Nordic-lymphoma : Nordic-lymphoma and Norwegian Cancer Registry Kreftregisteret. Headed by Knut B. Smeland
Off-label use of anti-cancer drugs in Norway-a prospective cohort. Headed by Knut B. Smeland
Acclerate –the first-ever registry for Castleman disease patients - a research study designed to help physicians and researchers better understand Castleman disease, uncover patterns in the disease, and improve treatment. Collaboration with Castleman Disease Collaborative network (CDCN) ACCELERATE Patient Research Study - Castleman Disease Collaborative Network (cdcn.org)
Nordic registry for Castleman disease. Headed by Alexander Fosså and Troels Hammer, Rigshospitalet, Denmark